HealiusASX:HLS +1.39%49 EBIT per Share is A$-0.76 as of Dec. 2025. GuruFocus rates ASX:HLS with a GF Score™ of 49/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Healius ranks worse than 595237.5% on this metric.
Healius's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.76.
During the past 12 months, the average EBIT per Share Growth Rate of Healius was -54.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Healius's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Healius was 65.00% per year. The lowest was -35.70% per year. And the median was 3.80% per year.
ASX:HLS's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 12.75 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Healius's EBIT for the
six
months ended in Dec. 2025 was A$-35 Mil.
Healius (ASX:HLS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Healius EBIT per Share Related Terms
Healius EBIT per Share Historical Data
* Premium members only.
The historical data trend for Healius's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healius (ASX:HLS) has a EBIT per Share of A$-0.76 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Healius and its competitors. According to the industry distribution chart, Healius ranks #999999 out of 168 companies in the Medical Diagnostics & Research industry.
Is Healius' EBIT per Share too high?
Healius' current EBIT per Share is A$-0.76. Based on the distribution chart, Healius ranks #999999 out of 168 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Healius has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #999999 out of 168 companies for EBIT per Share. This places Healius in the lower half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current EBIT per Share is A$-0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current EBIT per Share is A$-0.76. Healius' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Healius (ASX:HLS), the current EBIT per Share is A$-0.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
EBIT per Share: A$-0.76
GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
49GF Score
Get the complete analysis for ASX:HLS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
